Could a diabetes drug help heart failure patients shed excess fluid?

NCT ID NCT05553938

First seen Jul 02, 2026 ยท Last updated Jul 02, 2026

Summary

This study investigates whether empagliflozin, a drug typically used for diabetes, can help people with worsening heart failure get rid of extra fluid. Researchers will give 60 participants either empagliflozin or a placebo for six weeks, alongside their usual diuretic medication, and measure how much salt and water their kidneys remove. The goal is to see if empagliflozin improves fluid balance, which could ease symptoms like swelling and shortness of breath.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
empagliflozin
What this could lead to
If successful, this could show that empagliflozin helps heart failure patients get rid of excess fluid more effectively, potentially reducing hospital visits.
What could go wrong
This is an early-phase study with only 60 participants, so results may not apply to all heart failure patients. The drug may not improve fluid removal or could cause side effects like dehydration or kidney issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Yale New Haven Hospital

    New Haven, Connecticut, 06520, United States

  • Yale University

    New Haven, Connecticut, 06520, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.